Drugs / Platinum
Platinum
also known as
C.i. 77795 · DDP · Metallic platinum · Platina l · Platinum black · Platinum metallicum · Platinum powder · Platinum, elemental
Trials 0
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Comparator or background therapy1 trial | ||||||
| Phase 2 | NCT02489409 Background | Oct 2015 → May 2018 | breast cancer | Xinjiang Medical University | Unknown | No outcome recorded |
News releases announcing trial results or a regulatory action · 29
| Date | Issuer | Release |
|---|---|---|
| 2026-04-12 | AbbVie | Results AbbVie Showcases Late‑Breaking Phase 2 Data for Mirvetuximab Soravtansine-gynx (ELAHERE®) in Platinum‑Sensitive Ovarian Cancer (PSOC) at SGO 2026 abbvie.com ↗
Findings highlight mirvetuximab soravtansine's potential across the ovarian cancer treatment continuum. |
| 2026-01-15 | CureLab Oncology | Results Novel DNA-based therapy achieves reduction in mortality in resistant ovarian cancer curelaboncology.com ↗
The research showed patients who received Elenagen plus chemotherapy lived significantly longer than those who received chemotherapy alone. |
| 2025-12-08 | Coherus Oncology, Inc. | Results Coherus Announces Six-Year JUPITER-02 Follow-up Results Showing LOQTORZI® plus Chemotherapy Nearly Doubles Median Overall Survival in Nasopharyngeal Carcinoma coherus.com ↗ |
| 2025-09-08 | Shanghai Henlius Biotech | Results Henlius Showcased 9 Study Findings on Serplulimab at 2025 WCLC with 3 Oral Presentations henlius.com ↗
These findings indicated that a dose-reduced bevacizumab regimen combined with serplulimab and platinum-based doublet chemotherapy exhibited promising efficacy and manageable safety for patients with EGFR-TKI-resistant nsq-NSCLC. |
| 2024-08-27 | Janssen Research & Development, LLC | Regulatory European Commission approves RYBREVANT®▼ (amivantamab) in combination with chemotherapy for the treatment of adult patients with advanced EGFR-mutated non-small cell lung cancer after failure of prior therapy jnj.com ↗ |
| 2022-09-11 | AbbVie | Results ImmunoGen Presents Additional Analyses Evaluating Mirvetuximab Soravtansine in Ovarian Cancer at ESMO abbvie.com ↗
today announced findings from an analysis of patient-reported outcomes (PROs) with mirvetuximab soravtansine (mirvetuximab) versus chemotherapy in the randomized Phase 3 FORWARD I study in platinum-resistant ovarian cancer. |
| 2022-09-10 | CureLab Oncology | Results ESMO 2022: Interim Results for Treatment of Platinum-Resistant Ovarian Cancer with p62 Plasmid DNA Show Statistically Significant Changes in Progression-Free Survival curelaboncology.com ↗
A statistically significant prolongation of PFS was clearly demonstrated in the trial and continues to extend as the trial continues. |
| 2022-01-24 | BeOne Medicines | Results BeiGene Announces Positive Findings from Phase 3 Trial of Tislelizumab in Combination with Chemotherapy in First-Line Gastric or Gastroesophageal Junction Cancer beonemedicines.com ↗
At the interim analysis, tislelizumab in combination with chemotherapy met the primary endpoint of overall survival (OS) in patients with PD-L1 expression, with additional follow-up needed to assess OS benefits in the intention-to-treat (ITT) population. |
| 2021-12-10 | BeOne Medicines | Results BeiGene Presents Results from Phase 3 Trial of Tislelizumab in Nasopharyngeal Cancer at ESMO Immuno-Oncology Congress 2021 beonemedicines.com ↗
In RATIONALE 309, tislelizumab in combination with chemotherapy significantly prolonged progression-free survival for patients, with survival benefit observed across patient subgroups |
| 2021-09-15 | Coherus Oncology, Inc. | Results Coherus and Junshi Biosciences Announce Results from Phase 3 Study of Toripalimab Published in September Issue of Nature Medicine coherus.com ↗
Toripalimab plus standard chemotherapy demonstrates improvement in PFS in first-line advanced nasopharyngeal carcinoma |
| 2021-09-13 | Coherus Oncology, Inc. | Results Positive Interim Results of CHOICE-01 Study Evaluating Coherus' and Junshi Biosciences’ Toripalimab for First Line Treatment of Non-Small Cell Lung Cancer Presented at World Conference on Lung Cancer coherus.com ↗
The interim analysis met the primary endpoint, demonstrating a statistically significant and clinically meaningful improvement in progression free survival (PFS) per RECIST v1.1 compared to chemotherapy alone. |
| 2021-05-07 | AstraZeneca | Results Imfinzi and tremelimumab with chemotherapy demonstrated overall survival benefit in POSEIDON trial for 1st-line Stage IV non-small cell lung cancer astrazeneca.com ↗ |
| 2021-01-13 | BeOne Medicines | Regulatory China National Medical Products Administration Approves Tislelizumab in Combination with Chemotherapy in First-Line Advanced Squamous Non-Small Cell Lung Cancer beonemedicines.com ↗
The China National Medical Products Administration (NMPA) has granted tislelizumab full approval for first-line treatment of patients with advanced squamous non-small cell lung cancer (NSCLC) in combination with chemotherapy. |
| 2020-08-11 | Bristol-Myers Squibb | Results CheckMate -649, a Phase 3 Trial Evaluating Opdivo (nivolumab) Plus Chemotherapy vs. Chemotherapy, Meets Primary Endpoints Demonstrating Superior Overall Survival and Progression-Free Survival in First-Line Treatment of Gastric and Esophageal Cancers bms.com ↗
Bristol Myers Squibb (NYSE: BMY) today announced that CheckMate -649, a pivotal Phase 3 trial evaluating Opdivo (nivolumab) plus chemotherapy compared to chemotherapy alone as a first-line treatment for metastatic gastric cancer, gastroesophageal junction (GEJ) cancer or esophageal adenocarcinoma, met both primary endpoints of overall survival (OS) at a pre-specified interim analysis and progression-free survival (PFS) at final analysis in patients whose tumors express PD-L1 with a combined positive score (CPS) ≥ 5. |
| 2020-05-29 | BeOne Medicines | Results BeiGene Presents Phase 3 Data on Tislelizumab Combined with Chemotherapy for the Treatment of Patients with Advanced Squamous Non-Small Cell Lung Cancer at the 2020 American Society of Clinical Oncology (ASCO) Virtual Scientific Program beonemedicines.com ↗
Phase 3 results comparing tislelizumab plus chemotherapy to chemotherapy alone met its primary endpoint |
| 2019-10-28 | AstraZeneca | Results Imfinzi and Imfinzi plus tremelimumab delayed disease progression in Phase III POSEIDON trial for 1st-line treatment of Stage IV non-small cell lung cancer astrazeneca.com ↗
The trial met a primary endpoint by showing a statistically significant and clinically meaningful improvement in the final PFS analysis in patients treated with the combination of Imfinzi and a broad choice of five standard-of-care platinum-based chemotherapy options vs. chemotherapy alone. |
| 2019-04-01 | Merck Sharp & Dohme LLC | Regulatory Merck’s KEYTRUDA® (pembrolizumab) Approved in China for First-Line Treatment of Metastatic Nonsquamous Non-Small Cell Lung Cancer (NSCLC) in Combination with Chemotherapy merck.com ↗
Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced that KEYTRUDA, Merck’s anti-PD-1 therapy, has been approved by the National Medical Products Administration (NMPA) in combination with pemetrexed and platinum chemotherapy for the first-line treatment of patients with metastatic nonsquamous non-small cell lung cancer (NSCLC), with no EGFR or ALK genomic tumor aberrations. |
| 2019-03-19 | SOTIO a.s. | Results SOTIO’s DCVAC/OvCa Significantly Improves Survival in Patients with Recurrent Ovarian Cancer sotio.com ↗
The combination of chemotherapy and immunotherapy corresponded with 73% survival at two years, compared to 41% survival when chemotherapy was used alone. |
| 2018-06-04 | SOTIO a.s. | Results Phase II Clinical Trials of DCVAC Show Significant Benefit for Patients with Ovarian and Lung Cancer sotio.com ↗
Patients that received DCVAC have an almost 44% lower risk of dying compared to those who received chemotherapy only. |
| 2017-12-08 | Eli Lilly and Company | Results Lilly Reports Top-Line Results from CYRAMZA® (ramucirumab) Phase 3 Study in First-Line Advanced Gastric Cancer lilly.com ↗
The trial met its primary endpoint of progression-free survival (PFS) but did not improve overall survival (OS), a secondary endpoint. |
| 2017-11-29 | Imunon | Results Celsion Corporation Announces Positive Data from the First Cohort of Patients in the OVATION Study imunon.com ↗
In the first three patients dosed, GEN-1 plus standard chemotherapy produced excellent results, with no dose limiting toxicities and highly promising efficacy signals leading to successful surgical outcomes. |
| 2017-11-29 | Imunon | Results Celsion Announces Presentation of OVATION Study Findings at the ASCO 2017 Annual Meeting imunon.com ↗
At the highest dose, 100% of patients achieved a R0, margin-negative, resection |
| 2017-09-10 | Merck Sharp & Dohme LLC | Results Merck’s KEYTRUDA® (pembrolizumab) Continues to Show Overall Survival Benefit Over Chemotherapy with Nearly Two Years Follow-Up in Previously Treated Patients with Advanced Urothelial Carcinoma, Post-Platinum Failure merck.com ↗
Updated data show that with median follow-up of 22.5 months, KEYTRUDA continues to demonstrate an overall survival (OS) benefit over investigator’s choice of paclitaxel, docetaxel or vinflunine as a second-line therapy, post-platinum failure, regardless of PD-L1 expression (HR, 0.70 [95% CI, 0.57-0.86], p=0.0003). |
| 2016-12-06 | Novartis Pharmaceuticals | Results Novartis announces Zykadia® first-line study results showing 16.6 month progression-free survival in patients with ALK+ advanced NSCLC novartis.com ↗
Results were presented during the Presidential Symposium at the 17 th World Conference on Lung Cancer (WCLC), hosted by the International Association for the Study of Lung Cancer (IASLC), in Vienna. |
| 2016-10-10 | Aprea Therapeutics | Results Aprea Therapeutics Announces Efficacy and Safety Data in High-Grade Serous Ovarian Cancer Patients Treated with APR-246 in Presentation at 2016 European Society for Medical Oncology (ESMO) Annual Meeting aprea.com ↗
Of 22 patients with radiologically measurable lesions, 3 had confirmed complete response, 10 had confirmed partial response, 8 had stable disease and 1 was not evaluable. |
| 2016-10-09 | Novartis Pharmaceuticals | Results Novartis ALK+ metastatic NSCLC therapy Zykadia® extends progression-free survival beyond 18 months in Phase II study novartis.com ↗
Median PFS by BIRC for Zykadia and chemotherapy were 5.4 months (95% CI: 4.1-6.9) vs. 1.6 months (95% CI: 1.4-2.8), respectively[4]. |
| 2016-03-22 | Verastem, Inc. | Results Verastem Announces Oral Presentation of Data Supporting the Preferential Targeting of Ovarian Cancer Stem Cells at the Society of Gynecologic Oncology’s 2016 Annual Meeting on Women’s Cancer verastem.com ↗
Three markers demonstrated a significant fold increase that correlated with platinum resistance: POSTN (4.1-fold), ALDH1A1 (5-fold), and SOX2 (14.5-fold). |
| 2004-07-29 | Eli Lilly and Company | Regulatory Gemzar Combination Therapy Receives European Regulatory Approvals for Treatment of Ovarian Cancer lilly.com ↗
Gemzar®(gemcitabine), approved to treat patients with pancreas, non-small-cell lung, metastatic breast and bladder cancers, receives approvals for a fifth indication. |
| 2004-06-09 | Astex Pharmaceuticals, Inc. | Results SuperGen Reports Promising Results from Phase I Study of Dacogen™ and Carboplatin for Treatment of Advanced Solid Tumors astx.com ↗
The maximum tolerated dose of decitabine in combination with carboplatin was identified as decitabine 135mg/m2 with the dose limiting toxicity of grade 4 febrile neutropenia. |
All press releases naming this drug 29 releases
Evidence & citations 11 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Platinum | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02489409 ↗ |
| Known as | C.i. 77795 | ChEMBL registry synonym — accepted as the source's own label CHEMBL1235478 ↗ |
| Known as | DDP | “DDP” NCT02489409 ↗ |
| Known as | Metallic platinum | ChEMBL registry synonym — accepted as the source's own label CHEMBL1235478 ↗ |
| Known as | Platina l | ChEMBL registry synonym — accepted as the source's own label CHEMBL1235478 ↗ |
| Known as | Platinum black | ChEMBL registry synonym — accepted as the source's own label CHEMBL1235478 ↗ |
| Known as | Platinum metallicum | ChEMBL registry synonym — accepted as the source's own label CHEMBL1235478 ↗ |
| Known as | Platinum powder | ChEMBL registry synonym — accepted as the source's own label CHEMBL1235478 ↗ |
| Known as | Platinum, elemental | ChEMBL registry synonym — accepted as the source's own label CHEMBL1235478 ↗ |
| Modality | Small molecule | — CHEMBL1235478 ↗ |
| Route | Intravenous | “Platinum (DDP): 30 mg/m2, iv 3h, d1-3” NCT02489409 ↗ |